Prof. Frederik L. Giesel is taking the new position of Co-Chair, and Prof. Akram Al-Ibraheem is joining as the first SAB member from the Middle East.

March 5, 2026 – Wiesbaden, Germany. The International Centers for Precision Oncology (QUANTALPHA ) Foundation announced key evolution to its Scientific Advisory Board (SAB). This Board is contributing with their visionary scientific leadership and groundbreaking expertise in Theranostics to all QUANTALPHA activities around the world, including the QUANTALPHA Center´s accreditation, the Academy for Theranostics, the evaluation of grants, as well as the creation of education and innovation-driven programs. Prof. Frederik L. Giesel, Head of Nuclear Medicine, University Hospital Duesseldorf, Germany, has been appointed Co-Chair of the SAB. He will collaborate with Prof. Richard P. Baum, Chair of the SAB. In addition, Prof. Akram Al Ibraheem, Chairman of the Nuclear Medicine Department at King Hussein Cancer Center, Amman, Jordan, has joined the SAB, further expanding the international span to 19 members across 9 countries, now including the Middle-East region.

“I am delighted to welcome Prof. Frederik L. Giesel as Co-Chair of the QUANTALPHA Scientific Advisory Board. His outstanding scientific expertise and deep commitment to advancing Theranostics make him an ideal partner in guiding the Board’s scientific agenda. I am also pleased to welcome Prof. Akram Al-Ibraheem as a new member of the SAB from the Middle-East. His collaboration with numerous leading global nuclear medicine associations will make a significant impact on our mission. I greatly value them both and look forward to working closely together to further strengthen the scientific impact and global mission of the QUANTALPHA Foundation”, stated Prof. Richard P. Baum, Chair of the QUANTALPHA Scientific Advisory Board, President of the QUANTALPHAAcademy for Theranostics, and Trustee of the QUANTALPHA Foundation.

Commenting on his new role, Prof. Frederik L. Giesel, Head of Nuclear Medicine, University Hospital Duesseldorf, Germany, said: “It is an honor to serve as Co-Chair of the QUANTALPHA Scientific Advisory Board. Collaborating with Prof. Richard P. Baum and our esteemed colleagues from around the world creates a powerful environment for advancing Theranostics. By harnessing our global expertise, we are committed to supporting groundbreaking research and ensuring that scientific progress translates into meaningful clinical benefits for cancer patients around the world.”